Opticell Ag+ Wound Dressings
Chytoform™ Chitosan-based Gelling Technology
Opticell with Chytoform™ technology is the next generation of chronic wound care dressings.
Chytoform gelling fiber is primarily composed of chitosan, a well-known biological material derived from crustacean shells. Chitosan’s unique chemistry, including a positive charge at physiological pH, has made it the center of much academic and clinical research 1-30. Medline’s Opticell dressings are the first application of this advanced biological material for use in chronic wound care, but chitosan has been used in other health care applications (e.g., topical hemostat, treatment of surgical wounds and traumatic injuries and in dietary supplements) because of its unique properties.
When Opticell with Chytoform™ technology comes into contact with moisture, it transform into a strong, absorbent and conformable gel that controls minor bleeding common in newly debrided wounds. These characteristics allow Opticell to deliver excellent outcomes.
- 1. Lord MS, Cheng B, McCarthy SJ, Jung M, Whitelock JM. The modulation of platelet adhesion and activation by chitosan through plasma and extracellular matrix proteins. Biomaterials 2011;32(28):6655-62.
- 2. Rao SB, Sharma CP. Use of chitosan as a biomaterial: studies on its safety and hemostatic potential. J Biomed Mater Res 1997; 34: 21-8
- 3. Ueno H, Mori T, Fujinaga T. Topical formulations and wound healing applications of chitosan. Adv Drug Deliv Rev 2001;52(2):105-15
- 4. Baldrick P. The safety of chitosan as a pharmaceutical excipient. Regul Toxicol Pharmacol 2010;56(3):290-9.
- 5. Chung MJ, Park JK, Park YI. Anti-inflammatory effects of low-molecular weight chitosan oligosaccharides in IgE-antigen complex-stimulated RBL-2H3 cells and asthma model mice. Int Immunophamacol. 12 (2): 453-9, 2012.
© Medline Industries, Inc. All rights reserved. Chytoform is a trademark and Opticell and Medline are registered trademarks of Medline Industries, Inc.